Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (5): 785-789    DOI: 10.31083/j.ejgo.2020.05.5466
Original Research Previous articles | Next articles
The effects of chemotherapy with anthracyclines vs capecitabine on tumour size, survival rate and estradiol levels in patients with locally advanced breast cancer
Huifen Zhen1, Fan Guo1, Xiaojun Zhang1, Miaomiao Jia1, Haibo Yang1, Yarong Yao1, Yuandong Li1, Jinnan Gao1, *()
1Department of Breast surgery, Shan Xi Bethune Hospital, Taiyuan ShanXi 030032, P. R. China
Download:  PDF(219KB)  ( 166 ) Full text   ( 4 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objectives: To investigate the therapeutic effect of anthracycline chemotherapy in advanced breast cancer and its impact on Estradiol and tumor size. Methods: A total of 136 breast cancer patients in our hospital were divided into NH group (anthracycline chemotherapy) and CG group (non-anthracycline chemotherapy). The clinical effects on patients in both groups were observed. The levels of estrone (E1), estradiol (E2) and follicle stimulating hormone (FSH) before and after treatment were measured. The tumor size, adverse reactions and 2-year survival rate of NH group and CG group were evaluated after 1-3 courses of treatment. Results: There was no significant difference in the serum E1, E2 and FSH levels before treatment between the NH group and the CG group (p > 0.05). After treatment, the levels of E1 and E2 in the NH group and the CG group were lower than those before treatment, and the FSH levels were higher than those before treatment (p < 0.05). Compared with the NH group, whilst the FSH levels were lower, the E1 and E2 levels in the CG group were significantly higher. There was no significant difference in the tumor size between the NH group and the CG group before treatment (p > 0.05). Compared with those of before treatment, the FSH levels in the NH group and the CG group after treatment were higher (p < 0.05). The tumor volume gradually decreased over the course of treatment, and the tumor size during treatment in the NH group was smaller than that of the CG group (p < 0.05). There was no significant difference between the two groups (p > 0.05). The 2-year survival rate of NG group and CG group was 82.3% and 71.3%, respectively with the NH group being significantly higher than that of the CG group. Conclusions: The effects of anthracycline on advanced breast cancer was better, showing lowered levels of serum E2, and decreased tumor volumes.
Key words:  Breast cancer      Anthracyclines      E2      Clinical efficacy     
Submitted:  11 January 2020      Accepted:  31 March 2020      Published:  15 October 2020     
*Corresponding Author(s):  JINNAN GAO     E-mail:  nj198012@126.com

Cite this article: 

Huifen Zhen, Fan Guo, Xiaojun Zhang, Miaomiao Jia, Haibo Yang, Yarong Yao, Yuandong Li, Jinnan Gao. The effects of chemotherapy with anthracyclines vs capecitabine on tumour size, survival rate and estradiol levels in patients with locally advanced breast cancer. European Journal of Gynaecological Oncology, 2020, 41(5): 785-789.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.05.5466     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I5/785

[1] Polyana Barbosa Silva, Millena Prata Jammal, Márcia Antoniazi Michelin, Eddie Fernando Cândido Murta. Phenotypic differences of tecidual TDCs obtained from breast cancer mice[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 689-698.
[2] Katselashvili Lika, Jokhadze Natia, Katcharava Margarita, Vardiashvili Nino. Breast Cancer Metastatic to Vulva - a Case Report[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 845-848.
[3] Hayal Uzelli Şimşek, Turgay Şimşek, Deniz Şahin, Sertaç Ata Güler, Nuh Zafer Cantürk, Nihat Zafer Utkan. Evaluation of the effect of surgical timing on systemic response to trauma in premenopausal patients by using cytokine levels[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 577-582.
[4] Isao Otsuka. Clear cell carcinoma of the vagina followed by breast cancer in a patient without prenatal diethylstilbestrol exposure[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 638-639.
[5] Luca Roncati, Maria Vadalà, Pepe Valentina, Veronica Corazzari, Beniamino Palmieri. Genomic profiling in gynaecological oncology: the future is now![J]. European Journal of Gynaecological Oncology, 2020, 41(3): 323-325.
[6] D. Korfias, J. Contis, M. Frangou-Plemenou, K. Gennatas, A. Kondis, D. Vlachodimitropoulos. Stem cells in ductal breast cancer: immunohistochemical expression of CD44, CD24, CD133, and ALDH-1 markers in 104 cases[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 36-41.
[7] A. Conversano, C. Balleyguier, M.K. De Fremicourt, H. Alkhashnam, C. Mazouni, J. Arfi-Rouche, N. Leymarie, F. Rimareix. Magnetic seed localisation for non-palpable lesions in patients undergoing breast conservative surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 48-53.
[8] S.Wang, W.J. Chen, Z.M. Song, Q. Li, X. Shen, Y.D. Wu, L. Zhu, Q.X. Ma, D.M. Xing. Long non-coding RNA ROR accelerates the progression of breast cancer via promoting stemness in MCF-10A cells[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 106-109.
[9] M. Englert-Golon, B. Burchardt, R. Słopień, N. Smolarek, S. Sajdak. Ovarian and endometrial cancer after breast cancer - three primary malignancies in a single patient[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 153-154.
[10] T. Aizawa, T. Maebayashi, N. Ishibashi, M. Sakaguchi. Bilateral organizing pneumonia after radiotherapy for bilateral synchronous breast cancers: a case report and literature review[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1051-1054.
[11] M. El Homsi, A. Barakat, R. Rammal, M. Haidar. Uterine metastasis from invasive ductal breast carcinoma mimicking fibroid features on MRI and detected by FDG PET/CT: role of SUVmax[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1079-1082.
[12] S. Dierckxsens, B. Geerinckx, M.T. Huizing, W.A.A. Tjalma. A review regarding the feasibility and accuracy of a sentinel lymph node biopsy after neo-adjuvant chemotherapy for breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 714-721.
[13] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781-786.
[14] S. Bertozzi, A. P. Londero, S. Bernardi, C. Cedolini. Applicability of the Notthingham Prognostic Index for predicting the survival of triple-negative invasive breast cancer in a single Italian center[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 787-790.
[15] C. Cedolini, S. Bertozzi, A. P. Londero, I. Pradelle, S. Bernardi, V. Londero, A. Uzzau, M. Bazzocchi, C. Zuiani, A. Risaliti. Risk factors for breast cancer development in patients with borderline breast lesions: a retrospective analysis of our outpatient facility[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 572-578.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] B. Soltész, J. Lukács, A. Penyige, R. Póka, B. Nagy. Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 547 -550 .
[3] Y. Li, C. Li, N. Li, L. Jiang, W. Yang, Y. Wang, B. Wu, C. Shi, Z. Zhu. RNAi silenced NUP88 gene suppresses growth and invasiveness of human breast cancer cell line MCF-7[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 634 -639 .
[4] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .
[5] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879 -882 .
[6] Z. Protrka, P. Arsenijevic, N. Jovic, S. Zivanovic, J. Djuric, A. Dimitrijevic. A case of uterine torsion in term pregnancy associated with placental abruption and intrauterine fetal demise[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 287 -289 .
[7] T. Ueno, H. Yabushita, K. Iwasaki, A. Wakatsuki. Role of adiponectin and leptin in non-diabetic, non-obese patients with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 199 -204 .
[8] P. Pimsi, W. Santimaleeworagun, S. Therasakvichya, N. Saengsukkasemsak, A. Laocharoenkeat. The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 242 -246 .
[9] F. Lai-Tiong. Dermatomyositis revealing a 18-year breast cancer recurrence[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 292 -293 .
[10] M.F. Benoit, K.A. O'Hanlan, M.S. Sten, C.L. Kosnik, D.M. Struck, M.S. O'Holleran, J. Cuff, D.M. Halliday, E.A. Kent. Incidental appendectomy at the time of gynecologic surgery[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 386 -389 .